Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOX1 | Q9Y5S8 | 10/20 | 0.65 |
| ▸ | GAA | P10253 | 9/20 | 0.65 |
| ▸ | MAPT | P10636 | 9/20 | 0.65 |
| ▸ | MEN1 | O00255 | 5/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.65 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.65 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.65 |
| ▸ | BCHE | P06276 | 2/20 | 0.65 |
| ▸ | ACHE | P22303 | 2/20 | 0.65 |
| ▸ | SNCA | P37840 | 2/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.65 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.65 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.65 |
| ▸ | MAOA | P21397 | 1/20 | 0.65 |
| ▸ | CNR1 | P21554 | 1/20 | 0.65 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.65 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.65 |
| ▸ | HTR2C | P28335 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phenothiazine SCHEMBL9114 | 0.79 | NOX1 (1.00) | NOX1GAAMAPTMEN1KMT2A | |
| Phenothiazine SCHEMBL2504207 | 0.79 | NOX1 (1.00) | NOX1GAAMAPTMEN1KMT2A | |
| Phenothiazine SCHEMBL29352248 | 0.79 | NOX1 (1.00) | NOX1GAAMAPTMEN1KMT2A | |
| Phenothiazine SCHEMBL6315328 | 0.79 | NOX1 (1.00) | NOX1GAAMAPTMEN1KMT2A | |
| Phenothiazine SCHEMBL29349533 | 0.79 | NOX1 (1.00) | NOX1GAAMAPTMEN1KMT2A | |
| Phenothiazine SCHEMBL10383573 | 0.79 | NOX1 (0.77) | NOX1GAAMAPTMEN1KMT2A | |
| Phenothiazine SCHEMBL9347283 | 0.78 | NOX1 (0.85) | NOX1GAAMAPTMEN1KMT2A | |
| SCHEMBL5136043 | 0.77 | NOX1 (0.60) | NOX1GAAMAPTMEN1KMT2A | |
| Phenothiazine SCHEMBL23683396 | 0.77 | NOX1 (0.94) | NOX1GAAMAPTMEN1KMT2A | |
| Phenothiazine SCHEMBL22467847 | 0.77 | NOX1 (0.94) | NOX1GAAMAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103275091-A | Ixabepilone total synthesis | SHENZHEN JATIE PHARMACEUTICAL CO LTD | 2013-09-04 | — | — | CN | claimed |
| CN-1732172-A | Epothilone derivatives | NOVARTIS AG (CH) | 2006-02-08 | — | — | CN | claimed |
| US-20060014796-A1 | Epothilone derivatives | DENNI-DISCHERT DONATIENNE | 2006-01-19 | — | — | US | claimed |
| EP-1581536-A2 | EPOTHILONE DERIVATIVES | Novartis AG (CH) | 2005-10-05 | — | — | EP | claimed |
| WO-2004056832-A2 | EPOTHILONE DERIVATIVES | NOVARTIS AG (CH) | 2004-07-08 | — | — | WO | claimed |
| US-20240067646-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | HOFFMANN-LA ROCHE INC. | 2024-02-29 | — | — | US | disclosed |
| US-20230310651-A1 | METHODS FOR MODULATING RNA SPLICING | PTC THERAPEUTICS, INC. (US) | 2023-10-05 | — | — | US | disclosed |
| EP-4249472-A2 | METHODS FOR MODULATING RNA SPLICING | PTC Therapeutics, Inc. (US) | 2023-09-27 | — | — | EP | disclosed |
| US-11753407-B2 | Compounds for treating spinal muscular atrophy | PTC THERAPEUTICS, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-20230272367-A1 | METHODS FOR MODULATING RNA SPLICING | PTC THERAPEUTICS, INC. (US) | 2023-08-31 | — | — | US | disclosed |
| EP-3644996-B1 | METHODS FOR TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS INC (US) | 2023-07-26 | — | — | EP | disclosed |
| US-11702646-B2 | Methods for modulating RNA splicing | PTC THERAPEUTICS, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| WO-2013112788-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC THERAPEUTICS, INC. (US) | 2013-08-01 | — | — | WO | disclosed |
| WO-2013101974-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC THERAPEUTICS, INC. (US) | 2013-07-04 | — | — | WO | disclosed |
| CN-100384851-C | Epothilone derivatives | NOVARTIS AG (CH) | 2008-04-30 | — | — | CN | disclosed |
| US-7317100-B2 | Epothilone derivatives | NOVARTIS AG (CH) | 2008-01-08 | — | — | US | disclosed |
| CN-1732172-A | Epothilone derivatives | NOVARTIS AG (CH) | 2006-02-08 | — | — | CN | disclosed |
| US-20060014796-A1 | Epothilone derivatives | DENNI-DISCHERT DONATIENNE | 2006-01-19 | — | — | US | disclosed |
| EP-1581536-A2 | EPOTHILONE DERIVATIVES | Novartis AG (CH) | 2005-10-05 | — | — | EP | disclosed |
| WO-2004056832-A2 | EPOTHILONE DERIVATIVES | NOVARTIS AG (CH) | 2004-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240067646-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | SMN1; SMN2, CPT1B, GYS1 | NOX1 3246/4885GAA 13/4885MAPT 330/4885 |
| US-20230272367-A1 | METHODS FOR MODULATING RNA SPLICING | RBM17, SNRPE, HNRNPM | NOX1 3874/4885GAA 4175/4885MAPT 4001/4885 |
| US-11702646-B2 | Methods for modulating RNA splicing | RBM17, SNRPE, HNRNPM | NOX1 3874/4885GAA 4175/4885MAPT 4001/4885 |
| US-20060014796-A1 | Epothilone derivatives | CYP4A11, CYP51A1, EPOR | NOX1 961/4885GAA 4128/4885MAPT 3315/4885 |
| US-20230310651-A1 | METHODS FOR MODULATING RNA SPLICING | RBM17, SNRPE, RBM3 | NOX1 4003/4885GAA 3936/4885MAPT 3617/4885 |
| US-11753407-B2 | Compounds for treating spinal muscular atrophy | SMN1; SMN2, CPT1B, GYS1 | NOX1 3671/4885GAA 22/4885MAPT 265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.